ReviewGlycobiology2016
"Siglec"ting the allergic response for therapeutic targeting.
Review in Glycobiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 31 citations in OpenAlex.
- Advances in the Management of Mediator-Related Symptoms in Non-Advanced Systemic Mastocytosis.ImmunoTargets and therapy · 2026Review
- Elevated expression of SIGLEC8 in skin cutaneous melanoma predicts better prognosis associated with hematopoietic cell lineage pathway.Discover oncology · 2025Article
- Siglecs in allergy and asthma.Molecular aspects of medicine · 2023Review
- Subsets of Eosinophils in Asthma, a Challenge for Precise Treatment.International journal of molecular sciences · 2023Review
- Edible bird's nest, an Asian health food supplement, possesses anti-inflammatory responses in restoring the symptoms of atopic dermatitis: An analysis of signaling cascades.Frontiers in pharmacology · 2022Article
- Rethinking neutrophils and eosinophils in chronic rhinosinusitis.The Journal of allergy and clinical immunology · 2021Review
- Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference.The Journal of allergy and clinical immunology · 2021Article
- A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation.Mucosal immunology · 2021Article
- Review
- Eosinophil and mast cell Siglecs: From biology to drug target.Journal of leukocyte biology · 2020Review
- Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts.Theranostics · 2020Review
- Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis.JCI insight · 2019Article
- Mast Cell-Specific Expression of Human Siglec-8 in Conditional Knock-in Mice.International journal of molecular sciences · 2018Article
- Article
- The eosinophil: For better or worse, in sickness and in health.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2018Review
- Transcriptional profiling of eosinophil subsets in interleukin-5 transgenic mice.Journal of leukocyte biology · 2018Article
- Frontline Science: Characterization of a novel mouse strain expressing human Siglec-8 only on eosinophils.Journal of leukocyte biology · 2018Article
- Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells.The Journal of allergy and clinical immunology · 2018Article
- Characterization of Siglec-8 Expression on Lavage Cells after Segmental Lung Allergen Challenge.International archives of allergy and immunology · 2018Article
- Exploration of the Sialic Acid World.Advances in carbohydrate chemistry and biochemistry · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
As a physician-scientist, I have pursued research related to translational immunology with the goal of improving our ability to diagnose and treat allergic, immunologic and other diseases involving eosinophils, basophils and mast cells. We have tried to delineate novel mechanisms of human disease, working whenever possible with primary human cells and tissues, attempting to identify targets that might be amenable to the development of new therapies. As a general strategy, we have compared eosinophils, basophils, mast cells and neutrophils to look for pathways in inflammation that were unique to distinct subsets of these cells. In doing so, the concepts of glycobiology did not enter my mind until we began noticing some intriguing functional differences involving selectins and their ligands among these cell types. One simple observation, that neutrophils were coated with a glycan that allowed them to interact with an endothelial adhesion molecule while eosinophils lacked this structure, pried open the glyco-door for me. Fruitful collaborations with card-carrying glycobiologists soon followed that have forever positively influenced our science, and have enhanced our hypotheses, experimental design, research opportunities and discoveries. Within a few years, we helped to discover Siglec-8, an I-type lectin expressed only on human eosinophils, basophils, mast cells. This receptor, together with its closest mouse counterpart Siglec-F, has been the primary focus of our work now for over a decade. If not for those in the fields of glycobiology and glycoimmunology, my lab would not have made much progress toward the goal of leveraging Siglec-8 for therapeutic purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.